Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 1:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post PV MF Clear all
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Physician's Choice medications
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 16, 2026, 1:15 PM EDT
Completed Phase 2 Interventional

Actuate 1901: 9-ING-41 in Myelofibrosis

NCT04218071
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib, 9-ING-41
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Augusta, Georgia • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 16, 2026, 1:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

NCT02718300
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Parsaclisib, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 16, 2026, 1:15 PM EDT
Active, not recruiting Phase 3 Interventional Results available

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414
View directory record Official record
Conditions
Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Anemia
Interventions
ACE-536, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
14
States / cities
Los Angeles, California • Orlando, Florida • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 16, 2026, 1:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

NCT05280509
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Interventions
TL-895, Ruxolitinib
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Canton, Ohio • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 16, 2026, 1:15 PM EDT
Not listed Phase 1 Interventional

A Safety and Tolerability Study of Jaktinib

NCT05279001
View directory record Official record
Conditions
Myelofibrosis
Interventions
Jaktinib Hydrochloride Tablet
Drug
Lead sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 16, 2026, 1:15 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pelabresib, Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 16, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

NCT02124746
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia
Interventions
Momelotinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
15
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 16, 2026, 1:15 PM EDT
Terminated Phase 3 Interventional Results available

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

NCT01773187
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Best Available Therapy
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 16, 2026, 1:15 PM EDT
Terminated Phase 3 Interventional Results available

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

NCT02055781
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Best Available Therapy
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 16, 2026, 1:15 PM EDT
Terminated Phase 1 Interventional

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

NCT03373877
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
PU-H71, Ruxolitinib
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
New Haven, Connecticut • New Orleans, Louisiana • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 16, 2026, 1:15 PM EDT
Recruiting No phase listed Observational

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

NCT07362225
View directory record Official record
Conditions
Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF), Myelofibrosis, Myelofibrosis (MF), Myelofibrosis, Primary, Myelofibrosis, Post ET, Myelofibrosis, Post PV, Myelofibrosis (PMF), Myelofibrosis，MF, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations, MF, Secondary Myelofibrosis, Secondary Myelofibrosis in Myeloproliferative Disease, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Post-Polycythemia Vera Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-PV MF, Post-Essential Thrombocythemia Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-ET MF, Pre-fibrotic Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Disorders, Myeloproliferative Disorders (MPD), Myeloproliferative Neoplasms (MPNs), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis, Myeloproliferative Neoplasm With 10% Blasts or Higher, Myeloproliferative Neoplasms, MPN, MPN (Myeloproliferative Neoplasms), MPN-associated Myelofibrosis, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Not Otherwise Specified, Accelerated Phase MPN, Accelerated Phase Myeloproliferative Neoplasm, Blast Phase MPN, Blast Phase Myeloproliferative Neoplasm, Thrombocythemia Myelofibrosis (PET-MF), Thrombocythemia, Essential, Thrombocythemia, Hemorrhagic, Agnogenic Myeloid Metaplasia, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, MDS/MPN Crossover Syndromes
Interventions
Not listed
Lead sponsor
MPN Research Foundation
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 16, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Pomalidomide for Myelofibrosis Patients

NCT00946270
View directory record Official record
Conditions
Polycythemia Vera, Thrombocythemia
Interventions
CC-4047, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 16, 2026, 1:15 PM EDT
Completed Phase 1 Interventional

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

NCT00631462
View directory record Official record
Conditions
Myelofibrosis
Interventions
TG101348
Drug
Lead sponsor
TargeGen
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
San Diego, California • Stanford, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2009 · Synced Sep 16, 2026, 1:15 PM EDT
Completed Phase 3 Interventional Results available

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

NCT00952289
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Ruxolitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
88
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Baldwin Park, California + 85 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 16, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

NCT01340651
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Winter Park, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 16, 2026, 1:15 PM EDT
Completed Phase 3 Interventional Results available

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

NCT01969838
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
Momelotinib, Ruxolitinib, Placebo to match momelotinib, Placebo to match ruxolitinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
11
States / cities
Phoenix, Arizona • Escondido, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 16, 2026, 1:15 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Interventions
Pelabresib, Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
New Haven, Connecticut • Jupiter, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 16, 2026, 1:15 PM EDT
Recruiting Phase 3 Interventional

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135
View directory record Official record
Conditions
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Interventions
Navtemadlin, Navtemadlin placebo, Ruxolitinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
58
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 16, 2026, 1:15 PM EDT
Completed Phase 2 Interventional

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

NCT01633372
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
itacitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Sep 16, 2026, 1:15 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

NCT03755518
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
FEDRATINIB
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Aurora, Colorado • Miami, Florida • Augusta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 16, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

NCT04884191
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
33
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 16, 2026, 1:15 PM EDT
Terminated Phase 1 Interventional

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

NCT03935555
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
PU-H71
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Larkspur, California • Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 16, 2026, 1:15 PM EDT
Terminated Phase 2 Interventional Results available

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

NCT02730884
View directory record Official record
Conditions
Leukemia, Myelofibrosis, Anemia, Splenomegaly
Interventions
Rigosertib, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 16, 2026, 1:15 PM EDT